[go: up one dir, main page]

SK287547B6 - Farmaceutické činidlo, ktoré obsahuje ako aktívnu zložku derivát benzamidu - Google Patents

Farmaceutické činidlo, ktoré obsahuje ako aktívnu zložku derivát benzamidu Download PDF

Info

Publication number
SK287547B6
SK287547B6 SK209-2002A SK2092002A SK287547B6 SK 287547 B6 SK287547 B6 SK 287547B6 SK 2092002 A SK2092002 A SK 2092002A SK 287547 B6 SK287547 B6 SK 287547B6
Authority
SK
Slovakia
Prior art keywords
sodium
group
glutamate
carbonate
arginine
Prior art date
Application number
SK209-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK2092002A3 (en
Inventor
Tsuneji Suzuki
Tomoyuki Ando
Masahiko Ishibashi
Masahiro Sakabe
Ikuo Sakai
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of SK2092002A3 publication Critical patent/SK2092002A3/sk
Publication of SK287547B6 publication Critical patent/SK287547B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK209-2002A 1999-08-16 2000-08-16 Farmaceutické činidlo, ktoré obsahuje ako aktívnu zložku derivát benzamidu SK287547B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22955199A JP2001064177A (ja) 1999-08-16 1999-08-16 ベンズアミド誘導体を有効成分とする製剤
PCT/EP2000/008011 WO2001012193A1 (en) 1999-08-16 2000-08-16 Pharmaceutical agent comprising a benzamide derivative as active ingredient

Publications (2)

Publication Number Publication Date
SK2092002A3 SK2092002A3 (en) 2002-07-02
SK287547B6 true SK287547B6 (sk) 2011-01-04

Family

ID=16893948

Family Applications (1)

Application Number Title Priority Date Filing Date
SK209-2002A SK287547B6 (sk) 1999-08-16 2000-08-16 Farmaceutické činidlo, ktoré obsahuje ako aktívnu zložku derivát benzamidu

Country Status (29)

Country Link
EP (1) EP1207881B1 (hu)
JP (2) JP2001064177A (hu)
KR (1) KR100683876B1 (hu)
CN (1) CN1205931C (hu)
AR (1) AR031074A1 (hu)
AU (1) AU780151B2 (hu)
BG (1) BG65662B1 (hu)
BR (1) BR0013283A (hu)
CA (1) CA2380757C (hu)
CY (1) CY1116273T1 (hu)
CZ (1) CZ302924B6 (hu)
DK (1) DK1207881T3 (hu)
EE (1) EE05331B1 (hu)
ES (1) ES2536705T3 (hu)
HK (1) HK1046501B (hu)
HR (1) HRP20020181B1 (hu)
HU (1) HU230386B1 (hu)
IL (1) IL148169A0 (hu)
MX (1) MXPA02001575A (hu)
NO (1) NO328957B1 (hu)
NZ (1) NZ517356A (hu)
PL (1) PL201388B1 (hu)
PT (1) PT1207881E (hu)
RU (1) RU2257206C2 (hu)
SK (1) SK287547B6 (hu)
TW (1) TWI245630B (hu)
UA (1) UA73316C2 (hu)
WO (1) WO2001012193A1 (hu)
ZA (1) ZA200201466B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CA2423329A1 (en) * 2000-09-22 2003-03-20 Takeda Chemical Industries, Ltd. Solid preparations
AU2003220119A1 (en) 2002-03-07 2003-09-22 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
CN101646460A (zh) 2007-03-28 2010-02-10 参天制药株式会社 含有具有组蛋白脱乙酰化酶抑制作用的化合物作为有效成分的降眼压剂
KR101405615B1 (ko) * 2007-08-27 2014-06-12 (주)아모레퍼시픽 조성물 내 ｐＨ 조절을 통해 안정화된 벤즈아미드 화합물을함유하는 피부 외용제 조성물, 및 그 벤즈아미드 화합물안정화 방법
PT2350005E (pt) * 2008-08-29 2012-03-12 Bayer Pharma AG Polimorfo b de n-(2-aminofenil)-4-[n-(piridina-3-il)¿ metoxicarbonil-aminometil]-benzamida (ms-275)
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
EP2826477B1 (en) * 2013-04-04 2017-05-31 Daiichi Sankyo Company, Limited Solid composition of amino carboxylate salt
EP3513788B1 (en) 2015-03-19 2020-07-29 Daiichi Sankyo Company, Limited Solid preparation containing colorant
WO2016148263A1 (ja) 2015-03-19 2016-09-22 第一三共株式会社 抗酸化剤を含有する固形製剤
CN118286172A (zh) 2018-07-30 2024-07-05 第一三共株式会社 含有稳定剂的固体药物制剂
CN111867559A (zh) * 2019-01-25 2020-10-30 株式会社爱茉莉太平洋 含有苯甲酰胺化合物以及增溶剂的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer

Also Published As

Publication number Publication date
JP4854158B2 (ja) 2012-01-18
HUP0203226A3 (en) 2003-12-29
UA73316C2 (uk) 2005-07-15
AU780151B2 (en) 2005-03-03
HRP20020181B1 (hr) 2016-01-29
SK2092002A3 (en) 2002-07-02
CA2380757A1 (en) 2001-02-22
CZ302924B6 (cs) 2012-01-18
ZA200201466B (en) 2002-09-02
HU230386B1 (hu) 2016-03-29
EE200200073A (et) 2003-04-15
KR100683876B1 (ko) 2007-02-15
BR0013283A (pt) 2002-04-23
AU6442700A (en) 2001-03-13
JP2001064177A (ja) 2001-03-13
RU2257206C2 (ru) 2005-07-27
DK1207881T3 (da) 2015-06-22
CN1370068A (zh) 2002-09-18
ES2536705T3 (es) 2015-05-27
IL148169A0 (en) 2002-09-12
EP1207881A1 (en) 2002-05-29
CY1116273T1 (el) 2017-02-08
HRP20020181A2 (en) 2005-10-31
NO20020774L (no) 2002-03-04
AR031074A1 (es) 2003-09-10
KR20020020815A (ko) 2002-03-15
BG65662B1 (bg) 2009-05-29
JP2003507330A (ja) 2003-02-25
CA2380757C (en) 2009-01-27
PL201388B1 (pl) 2009-04-30
EE05331B1 (et) 2010-08-16
PL353449A1 (en) 2003-11-17
NO20020774D0 (no) 2002-02-15
RU2002106815A (ru) 2004-01-27
MXPA02001575A (es) 2003-10-14
EP1207881B1 (en) 2015-04-01
CZ2002540A3 (cs) 2002-06-12
CN1205931C (zh) 2005-06-15
HK1046501B (zh) 2005-09-30
HUP0203226A2 (hu) 2003-01-28
HK1046501A1 (en) 2003-01-17
PT1207881E (pt) 2015-06-05
TWI245630B (en) 2005-12-21
WO2001012193A1 (en) 2001-02-22
BG106516A (en) 2002-10-31
NZ517356A (en) 2003-07-25
NO328957B1 (no) 2010-06-28

Similar Documents

Publication Publication Date Title
US6936274B2 (en) Storage stable thyroxine active drug formulations and methods for their production
EP3417861B1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
SK287252B6 (sk) Farmaceutický prípravok s obsahom benzamidového derivátu
KR20100020480A (ko) Ｄｐｐ-ｉｖ 저해제를 위한 안정한 약제학적 제제
SK287547B6 (sk) Farmaceutické činidlo, ktoré obsahuje ako aktívnu zložku derivát benzamidu
JP2023540149A (ja) 抗ウイルス化合物の製剤
JP2021520400A (ja) エダラボン医薬組成物
CZ296381B6 (cs) Farmaceutický prostredek
JP3586471B2 (ja) トラセミド含有医薬組成物
CN103833713A (zh) 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
WO2012013116A1 (zh) 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法
US6482417B2 (en) Stable pharmaceutical formulation comprising torsemide modification II
WO2007143895A1 (fr) Solution supersaturée de chlorhydrate de gemcitabine et son procédé de préparation
EP4008316A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
US6784315B2 (en) Stilbene derivative crystal and method for producing the same
WO2023107082A1 (en) A film coated tablet of saxagliptin and at least one antioxidant processed with wet granulation
CN116212036A (zh) 一种阿糖胞苷缬氨酸酯盐酸盐的缓释制剂及其制备方法
CN103788044B (zh) 硝克柳胺化合物晶i型、其制法和其药物组合物与用途
WO2012062691A1 (en) Pharmaceutical compositions for treating hcv infections
KR20220014026A (ko) 나파모스타트 메실레이트와 덱사메타손 또는 그 염을 유효성분으로 포함하는 경구용 약제학적 조성물
EA023081B1 (ru) Инъекционная лекарственная форма флупиртина

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, BERL, DE

Effective date: 20110414

PC4A Assignment and transfer of rights

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, MONHEIM, DE

Free format text: FORMER OWNER: BAYER PHARMA AG, BERLIN, DE

Effective date: 20130226

TC4A Change of owner's name

Owner name: BAYER PHARMA AG, BERLIN, DE

Effective date: 20130606

MK4A Expiry of patent

Expiry date: 20200816